Our study suggests that S100A9 suppresses the anti-tumor immune responses by enhancing the enrichment of granulocytic MDSCs and reducing the recruitment and activation of cytotoxic T cells within SCLC tumors (Fig. 6C). This evidence concerns the gene S100A9 and neoplasm.